On April 5, 2023 at 10:13:59 ET an unusually large
$1,645.00K block of Call contracts in AstraZeneca
(AZN) was sold,
with a strike price of $70.00 / share, expiring in 72 days (on June 16, 2023).
Fintel tracks all large options trades, and the premium spent on this trade was 4.12 sigmas above the mean, placing it in the 100.00 percentile of all recent large trades made in AZN options.
This trade was first picked up on Fintel’s real time Unusual Option Trades
tool, where unusual option trades are highlighted.
Analyst Price Forecast Suggests 14.17% Upside
As of March 30, 2023,
the average one-year price target for AstraZeneca is $80.21.
The forecasts range from a low of $42.24 to a high of $112.96.
The average price target represents an increase of 14.17% from its latest reported closing price of $70.25.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for AstraZeneca
is $47,467MM, an increase of 7.03%.
The projected annual non-GAAP EPS
is $7.66.
What is the Fund Sentiment?
There are 2155 funds or institutions reporting positions in AstraZeneca.
This is an increase
of
117
owner(s) or 5.74% in the last quarter.
Average portfolio weight of all funds dedicated to AZN is 0.73%,
a decrease
of 0.31%.
Total shares owned by institutions decreased
in the last three months by 0.37% to 891,049K shares.
The put/call ratio of AZN is 0.98, indicating a
bullish
outlook.
What are Large Shareholders Doing?
Price T Rowe Associates
holds 68,592K shares
representing 4.43% ownership of the company.
In it’s prior filing, the firm reported owning 75,385K shares, representing
a decrease
of 9.90%.
The firm
increased
its portfolio allocation in AZN by 10.34% over the last quarter.
Wellington Management Group Llp
holds 54,606K shares
representing 3.52% ownership of the company.
In it’s prior filing, the firm reported owning 52,247K shares, representing
an increase
of 4.32%.
The firm
decreased
its portfolio allocation in AZN by 99.98% over the last quarter.
Primecap Management
holds 44,987K shares
representing 2.90% ownership of the company.
In it’s prior filing, the firm reported owning 45,614K shares, representing
a decrease
of 1.39%.
The firm
decreased
its portfolio allocation in AZN by 99.88% over the last quarter.
Capital International Investors
holds 40,798K shares
representing 2.63% ownership of the company.
In it’s prior filing, the firm reported owning 40,326K shares, representing
an increase
of 1.16%.
The firm
increased
its portfolio allocation in AZN by 15.15% over the last quarter.
AWSHX – WASHINGTON MUTUAL INVESTORS FUND
holds 27,870K shares
representing 1.80% ownership of the company.
In it’s prior filing, the firm reported owning 27,087K shares, representing
an increase
of 2.81%.
The firm
increased
its portfolio allocation in AZN by 9.86% over the last quarter.
Astrazeneca Background Information
(This description is provided by the company.)
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
